IVBIY News and Press, Innovent Biologics Inc ADR From 12/17/25

Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature PR Newswire SAN FRANCISCO and SUZHOU, China , Dec. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno...

Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity PR Newswire After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectiv...

Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody PR Newswire SAN FRANCISCO and SUZHOU, China , Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc....

Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis PR Newswire SAN FRANCISCO and SUZHOU, China , Dec. 8, 2025 /PRNewswire/ -- Innovent Biologic...

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma PR Newswire SAN FRANCISCO and SUZHOU, China , Dec. 7, 2025 /PRNewswire/ -- Innovent Biolog...

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List PR Newswire SAN FRANCISCO and SUZHOU, China , Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801),...

Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies PR Newswire SAN FRANCISCO and SUZHOU, China , Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global s...

China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval PR Newswire PECONDLE ® (picankibart injection) has received approval from China's National Medical Products Administration (NMPA) for the treatment...

Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population PR Newswire SAN FRANCISCO and SUZHOU, China , Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (H...

Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value PR Newswire SAN FRANCISCO and SUZHOU, China , Nov. 23, 2025 /PRNewswire/ -- Innovent Biologics (Stock Code: 01801.HK), a world-class bio...